Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): Potential clinical implications

Oncotarget

Volumn 8, Issue 20, 2017, Pages 33614-33620

  Hahn, Andrew W ^a   Gill, David M ^a   Maughan, Benjamin ^a   Agarwal, Archana ^a   Arjyal, Lubina ^a   Gupta, Sumati ^a   Streeter, Jessica ^b   Bailey, Erin ^b   Pal, Sumanta K ^c   Agarwal, Neeraj ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Circulating tumor DNA NGS; Correlation; Metastatic renal cell carcinoma; Tumor tissue NGS

Indexed keywords

CIRCULATING TUMOR DNA; DNA; UNCLASSIFIED DRUG; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER TISSUE; CLINICAL ARTICLE; DNA REPAIR; EPIGENETICS; FEMALE; GENE MUTATION; GENOMIC ALTERATION; HUMAN; HUMAN TISSUE; KIDNEY METASTASIS; MALE; MOLECULAR GENETICS; NEXT GENERATION SEQUENCING; CANCER STAGING; GENETIC VARIATION; GENETICS; HIGH THROUGHPUT SEQUENCING; KIDNEY TUMOR; LIQUID BIOPSY; METASTASIS; MIDDLE AGED; RENAL CELL CARCINOMA;

ADULT; AGED; BIOMARKERS, TUMOR; CARCINOMA, RENAL CELL; CIRCULATING TUMOR DNA; DNA, NEOPLASM; FEMALE; GENETIC VARIATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; KIDNEY NEOPLASMS; LIQUID BIOPSY; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING;

EID: 85019205804     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.16833     Document Type: Article

References (19)

1. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, et al, and CheckMate 025 Investigators. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015; 373:1803-13. doi: 10.1056/NEJMoa1510665
2. Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F, Roth BJ, Peltola K, Lee JL, Heng DY, Schmidinger M, et al, and METEOR investigators. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016; 17:917-27. doi: 10.1016/S1470-2045(16)30107-3
3. Eichelberg C, Vervenne WL, De Santis M, Fischer von Weikersthal L, Goebell PJ, Lerchenmüller C, Zimmermann U, Bos MM, Freier W, Schirrmacher-Memmel S, Staehler M, Pahernik S, Los M, et al. SWITCH: a randomised, sequential, open-label study to evaluate the efficacy and safety of sorafenib-sunitinib versus sunitinib-sorafenib in the treatment of metastatic renal cell cancer. Eur Urol. 2015; 68:837-47. doi: 10.1016/j.eururo.2015.04.017
4. Motzer RJ, Barrios CH, Kim TM, Falcon S, Cosgriff T, Harker WG, Srimuninnimit V, Pittman K, Sabbatini R, Rha SY, Flaig TW, Page R, Bavbek S, et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014; 32:2765-72. doi: 10.1200/JCO.2013.54.6911
5. Hutson TE, Escudier B, Esteban E, Bjarnason GA, Lim HY, Pittman KB, Senico P, Niethammer A, Lu DR, Hariharan S, Motzer RJ. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014; 32:760-67. doi: 10.1200/JCO.2013.50.3961
6. Wells JC, Stukalin I, Norton C, Srinivas S, Lee JL, Donskov F, Bjarnason GA, Yamamoto H, Beuselinck B, Rini BI, Knox JJ, Agarwal N, Ernst DS, et al. Third-line targeted therapy in metastatic renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium. Eur Urol. 2017; 71:204-09. doi: 10.1016/j. eururo.2016.05.049
7. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, Schnall-Levin M, White J, Sanford EM, An P, Sun J, Juhn F, Brennan K, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013; 31:1023-31 doi: 10.1038/nbt.2696
8. Lanman RB, Mortimer SA, Zill OA, Sebisanovic D, Lopez R, Blau S, Collisson EA, Divers SG, Hoon DS, Kopetz ES, Lee J, Nikolinakos PG, Baca AM, et al. Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA. PLoS One. 2015; 10:e0140712. doi: 10.1371/journal.pone.0140712
9. Kuderer NM, Burton KA, Blau S, Rose AL, Parker S, Lyman GH, Blau CA. Comparison of 2 commercially available next-generation sequencing platforms in oncology. JAMA Oncol. 2016. doi: 10.1001/jamaoncol.2016.4983
10. Chae YK, Davis AA, Carneiro BA, Chandra S, Mohindra N, Kalyan A, Kaplan J, Matsangou M, Pai S, Costa R, Jovanovic B, Cristofanilli M, Platanias LC, Giles FJ. Concordance between genomic alterations assessed by nextgeneration sequencing in tumor tissue or circulating cellfree DNA. Oncotarget. 2016; 7:65364-73. doi: 10.18632/oncotarget.11692
11. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015; 372:2509-20. doi: 10.1056/NEJMoa1500596
12. Gerlinger M, Horswell S, Larkin J, Rowan AJ, Salm MP, Varela I, Fisher R, McGranahan N, Matthews N, Santos CR, Martinez P, Phillimore B, Begum S, et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet. 2014; 46:225-33. doi: 10.1038/ng.2891
13. Calvo E, Schmidinger M, Heng DY, Grünwald V, Escudier B. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy. Cancer Treat Rev. 2016; 50:109-17. doi: 10.1016/j. ctrv.2016.09.002
14. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366:883-92. doi: 10.1056/NEJMoa1113205
15. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, et al. Detection of circulating tumor DNA in early-and late-stage human malignancies. Sci Transl Med. 2014; 6:224ra24. doi: 10.1126/scitranslmed.3007094
16. Pal SK, Sonpavde G, Agarwal N, Vogelzang NJ, Srinivas S, Haas NB, Signoretti S, Lanman RB, Banks K, Choueiri TK. Evolution of circulating tumor DNA profile from first-line to second-line therapy in metastatic renal cell carcinoma. J Clin Oncol. 2017; 35:434. doi: 10.1200/JCO.2017.35.6_ suppl.434
17. Mok T, Wu YL, Lee JS, Yu CJ, Sriuranpong V, Sandoval-Tan J, Ladrera G, Thongprasert S, Srimuninnimit V, Liao M, Zhu Y, Zhou C, Fuerte F, et al. Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy. Clin Cancer Res. 2015; 21:3196-203. doi: 10.1158/1078-0432. CCR-14-2594
18. Kim ST, Lee WS, Lanman RB, Mortimer S, Zill OA, Kim KM, Jang KT, Kim SH, Park SH, Park JO, Park YS, Lim HY, Eltoukhy H, et al. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients. Oncotarget. 2015; 6:40360-69. doi: 10.18632/oncotarget.5465
19. Le Tourneau C, Delord JP, Gonçalves A, Gavoille C, Dubot C, Isambert N, Campone M, Trédan O, Massiani MA, Mauborgne C, Armanet S, Servant N, Bièche I, et al, and SHIVA investigators. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015; 16:1324-34. doi: 10.1016/S1470-2045(15)00188-6